Aequus Pharmaceuticals Inc. (CVE:AQS) Director Buys C$11,400.00 in Stock
Aequus Pharmaceuticals Inc. (CVE:AQS) Director Buys C$11,400.00 in Stock
(Get Rating)Aequus Pharmaceuticals Inc. (CVE:AQS – Get Rating) Director Doug Janzen acquired 285,000 shares of the business's stock in a transaction on Wednesday, November 30th. The shares were purchased at an average price of C$0.04 per share, with a total value of C$11,400.00. Following the transaction, the director now owns 12,553,800 shares in the company, valued at approximately C$502,152.
董事道格·揚岑在11月30日星期三的一筆交易中收購了該公司28.5萬股股票。這些股票是以每股0.04加元的平均價格購買的，總價值為11,400.00加元。交易完成後，董事現在擁有該公司12,553,800股，價值約502,152加元。
Doug Janzen also recently made the following trade(s):
道格·詹森最近還進行了以下交易：
- On Sunday, November 20th, Doug Janzen purchased 115,000 shares of Aequus Pharmaceuticals stock. The stock was bought at an average price of C$0.03 per share, with a total value of C$3,450.00.
- 11月20日，星期日，道格·詹森購買了11.5萬股Aequus製藥公司的股票。該股是以每股0.03加元的平均價格購買的，總價值為3,450.00加元。
Aequus Pharmaceuticals Stock Performance
Aequus製藥公司股票表現
Shares of AQS remained flat at C$0.03 during trading hours on Wednesday. 409,000 shares of the stock were exchanged, compared to its average volume of 64,529. The firm has a 50-day moving average of C$0.04 and a 200 day moving average of C$0.06. The company has a quick ratio of 0.70, a current ratio of 0.78 and a debt-to-equity ratio of 138.88. The stock has a market capitalization of C$3.98 million and a P/E ratio of -2.69. Aequus Pharmaceuticals Inc. has a 1-year low of C$0.02 and a 1-year high of C$0.12.
在週三的交易時段，AQS的股價持平於0.03加元。該股成交量為40.9萬股，而其平均成交量為64,529股。該公司的50日移動均線切入位在0.04加元，200日移動均線切入位在0.06加元。該公司的速動比率為0.70%，流動比率為0.78%，債務權益比率為138.88。該股市值為398萬加元，市盈率為-2.69倍。Aequus PharmPharmticals Inc.的股價跌至0.02加元的一年低點和0.12加元的一年高點。
About Aequus Pharmaceuticals
Aequus製藥公司簡介
(Get Rating)
(獲取評級)
Aequus Pharmaceuticals Inc, a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Evolve dry eye products for various symptoms involved with dry eye disease and blepharitis, including discomfort, stinging, burning, and dryness; and preservative free ophthalmic product.
Aequus製藥公司是一家專業製藥公司，在加拿大開發和銷售藥物。它專注於各種治療領域，包括神經學、眼科和移植。該公司銷售Vistian，這是一種眼科產品，用於降低開角型青光眼或高眼壓患者的高眼壓；他克莫司IR，一種治療和預防器官移植後急性排斥反應的免疫抑制劑；針對乾眼病和眼緣炎的各種症狀，包括不適、刺痛、灼熱和乾燥，開發乾眼產品；以及不含防腐劑的眼科產品。
Featured Articles
專題文章
- Santa Claus Rally? Here's What Needs to Happen
- Cosmos Holdings May be a Long-Term Buy with Short-Term Risk
- Dark Clouds Are Gathering For Cloud Stocks
- Hormel: Is This The Time To Buy?
- 3 Dividend Growers With Good 2023 Growth Prospects
- 聖誕老人拉力賽？以下是需要發生的事情
- Cosmos Holdings可能是具有短期風險的長期買入
- 烏雲雲集，雲股雲集
- 霍梅爾：現在是買進的時候嗎？
- 3個具有良好2023年增長前景的股息增長者
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得Aequus PharmPharmticals Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Aequus製藥和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。
